资讯

S4 Capital First Half 2025 Earnings: UK£0.033 loss per share (vs UK£0.02 loss in 1H 2024)

UK£22.3m (loss widened by 63% from 1H 2024). UK£0.033 loss per share (further deteriorated from UK£0.02 loss in 1H 2024).

Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to ...